ALLO
NASDAQ HealthcareAllogene Therapeutics, Inc. - Common Stock
Biotechnology
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $2.39 |
|---|---|
| 成交量 | 11,502,186 |
| 市值 | 791.75M |
| 贝塔系数 | 0.540 |
| RSI（14日） | 52.6 |
| 200日均线 | $1.56 |
| 50日均线 | $2.32 |
| 52周最高 | $4.46 |
| 52周最低 | $0.86 |
| Forward P/E | -3.20 |
| Price / Book | 1.87 |
🎯 投资策略评分
ALLO 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (46/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🎈 Over-Hyped (13/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ALLO in your text
粘贴任何文章、记录或帖子 — 工具将提取 ALLO 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.